Sorafenib Plus Tegafur-uracil (UFT) Versus Sorafenib as First Line Systemic Treatment for Patients With Advanced Stage HCC, Unresectable & Not Eligible for Local Ablation and/or TACE

NCT01539018 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
77
Enrollment
OTHER
Sponsor class

Stopped After interim results data showed no evidence of a difference between both groups

Conditions

Interventions

Sponsor

Egyptian Society of Liver Cancer